Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Spectroradiometer

By Drug Discovery Trends Editor | November 30, 2012

Spectral Evolution’s UDS-1100 spectroradiometer is designed to study the relationship between upwelling radiation reflected or emitted upward from the earth’s surface, and downwelling radiation directed toward the earth from the sun and atmosphere. This study can provide insight into the spectral characteristics of vegetation, soil and crops, forest canopies, ocean studies, climactic changes, environmental studies of ice and snow, hydrologic studies, and more.

The UDS-1100 is intended for surface reflectance measurements where it is inconvenient or impractical to take frequent reflectance panel reference scans, especially on days with shifting cloud cover. The UDS-1100 simultaneously measures upwelling and downwelling, can be mounted in towers, and features built-in DARWin Data Analysis software that permits automatic reflectance scanning for unattended operation.

The unit has a 320-1100 nm spectral range and can simultaneously measure full sky irradiance and surface radiation. It allows the user to choose communication modes, power operation, and mounting styles.  Date can be plotted and results can be reviewed in radiometric or photometric units, and current scans can be compared against libraries. Single and multiple spectral plots are available. The UDS-1100 automatically saves data as an ASCII file to third party software, with no extra export function necessary.
It is intended for use in vegetation studies, ocean studies, crop and soil scanning, water studies researching environmental quality, climactic studies, hydrologic studies, and studies of aerosols in the atmosphere.

Spectral Evolution


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50